...
search icon
xgn-img

Exagen Inc Share Price

XGN
NMQ
$3.28
+$0.04
(1.23%)
1D
Industry: Biotechnology Sector: Health Care

Exagen Inc Analyst Forecast

Exagen Inc Share Price Chart

Exagen Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$73.43M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
235.80K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.88
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.67 L
$12.23 H
$3.28

About Exagen Inc, Common Stock

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. more

Industry: BiotechnologySector: Health Care

Exagen Inc Stock Returns

Time FrameXGNSectorS&P500
1-Week Return-6.55%-1.08%-1.38%
1-Month Return-36.31%-0.47%-1.81%
3-Month Return-64.92%2.13%1.38%
6-Month Return-66.08%17.04%5.68%
1-Year Return-23.19%6.56%11.74%
3-Year Return28.12%16.78%65.15%
5-Year Return-81.98%34.34%73.68%
10-Year Return-80.83%137.88%260.03%

Exagen Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue41.98M48.30M45.56M52.55M55.64M[{"date":"2020-12-31","value":75.44,"profit":true},{"date":"2021-12-31","value":86.8,"profit":true},{"date":"2022-12-31","value":81.89,"profit":true},{"date":"2023-12-31","value":94.44,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue16.56M20.59M24.21M23.09M22.53M[{"date":"2020-12-31","value":68.39,"profit":true},{"date":"2021-12-31","value":85.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.37,"profit":true},{"date":"2024-12-31","value":93.04,"profit":true}]
Gross Profit25.42M27.71M21.35M29.46M33.11M[{"date":"2020-12-31","value":76.76,"profit":true},{"date":"2021-12-31","value":83.69,"profit":true},{"date":"2022-12-31","value":64.48,"profit":true},{"date":"2023-12-31","value":88.96,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin60.55%57.37%46.86%56.06%59.51%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.75,"profit":true},{"date":"2022-12-31","value":77.38,"profit":true},{"date":"2023-12-31","value":92.58,"profit":true},{"date":"2024-12-31","value":98.28,"profit":true}]
Operating Expenses40.60M51.78M67.40M52.29M46.75M[{"date":"2020-12-31","value":60.24,"profit":true},{"date":"2021-12-31","value":76.82,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":77.59,"profit":true},{"date":"2024-12-31","value":69.36,"profit":true}]
Operating Income(15.19M)(24.07M)(46.05M)(22.84M)(13.64M)[{"date":"2020-12-31","value":-1518500000,"profit":false},{"date":"2021-12-31","value":-2406700000,"profit":false},{"date":"2022-12-31","value":-4605100000,"profit":false},{"date":"2023-12-31","value":-2283700000,"profit":false},{"date":"2024-12-31","value":-1363600000,"profit":false}]
Total Non-Operating Income/Expense(4.15M)(5.23M)(3.24M)(2.38M)(2.93M)[{"date":"2020-12-31","value":-414600000,"profit":false},{"date":"2021-12-31","value":-523400000,"profit":false},{"date":"2022-12-31","value":-323600000,"profit":false},{"date":"2023-12-31","value":-238400000,"profit":false},{"date":"2024-12-31","value":-293400000,"profit":false}]
Pre-Tax Income(16.77M)(26.68M)(47.67M)(23.66M)(15.10M)[{"date":"2020-12-31","value":-1676600000,"profit":false},{"date":"2021-12-31","value":-2667600000,"profit":false},{"date":"2022-12-31","value":-4766900000,"profit":false},{"date":"2023-12-31","value":-2365600000,"profit":false},{"date":"2024-12-31","value":-1510300000,"profit":false}]
Income Taxes(79.00K)175.00K(282.00K)33.00K12.00K[{"date":"2020-12-31","value":-45.14,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-161.14,"profit":false},{"date":"2023-12-31","value":18.86,"profit":true},{"date":"2024-12-31","value":6.86,"profit":true}]
Income After Taxes(16.69M)(26.85M)(47.39M)(23.69M)(15.12M)[{"date":"2020-12-31","value":-1668700000,"profit":false},{"date":"2021-12-31","value":-2685100000,"profit":false},{"date":"2022-12-31","value":-4738700000,"profit":false},{"date":"2023-12-31","value":-2368900000,"profit":false},{"date":"2024-12-31","value":-1511500000,"profit":false}]
Income From Continuous Operations(16.69M)(26.85M)(47.39M)(32.47M)(15.12M)[{"date":"2020-12-31","value":-1668700000,"profit":false},{"date":"2021-12-31","value":-2685100000,"profit":false},{"date":"2022-12-31","value":-4738700000,"profit":false},{"date":"2023-12-31","value":-3247000000,"profit":false},{"date":"2024-12-31","value":-1511500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(16.69M)(26.85M)(47.39M)(23.69M)(15.12M)[{"date":"2020-12-31","value":-1668700000,"profit":false},{"date":"2021-12-31","value":-2685100000,"profit":false},{"date":"2022-12-31","value":-4738700000,"profit":false},{"date":"2023-12-31","value":-2368900000,"profit":false},{"date":"2024-12-31","value":-1511500000,"profit":false}]
EPS (Diluted)(1.32)(1.70)(2.68)(1.34)(0.83)[{"date":"2020-12-31","value":-132,"profit":false},{"date":"2021-12-31","value":-170,"profit":false},{"date":"2022-12-31","value":-268,"profit":false},{"date":"2023-12-31","value":-134,"profit":false},{"date":"2024-12-31","value":-82.54,"profit":false}]

Exagen Inc Ratios

Exagen Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

XGN
Cash Ratio 2.77
Current Ratio 4.08
Quick Ratio 3.81

Exagen Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

XGN
ROA (LTM) -14.66%
ROE (LTM) -122.81%

Exagen Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

XGN
Debt Ratio Lower is generally better. Negative is bad. 0.71
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.29

Exagen Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

XGN
Trailing PE NM
Forward PE NM
P/S (TTM) 1.15
P/B 4.14
Price/FCF 28
EV/R 1.03
EV/Ebitda NM

FAQs

What is Exagen Inc share price today?

Exagen Inc (XGN) share price today is $3.28

Can Indians buy Exagen Inc shares?

Yes, Indians can buy shares of Exagen Inc (XGN) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Exagen Inc be purchased?

Yes, you can purchase fractional shares of Exagen Inc (XGN) via the Vested app. You can start investing in Exagen Inc (XGN) with a minimum investment of $1.

How to invest in Exagen Inc shares from India?

You can invest in shares of Exagen Inc (XGN) via Vested in three simple steps:

  • Click on Sign Up or Invest in XGN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Exagen Inc shares
What is Exagen Inc 52-week high and low stock price?

The 52-week high price of Exagen Inc (XGN) is $12.23. The 52-week low price of Exagen Inc (XGN) is $2.67.

What is Exagen Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Exagen Inc (XGN) is

What is Exagen Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Exagen Inc (XGN) is 4.14

What is Exagen Inc dividend yield?

The dividend yield of Exagen Inc (XGN) is 0.00%

What is the Market Cap of Exagen Inc?

The market capitalization of Exagen Inc (XGN) is $73.43M

What is Exagen Inc's stock symbol?

The stock symbol (or ticker) of Exagen Inc is XGN

How Can Investors Use Exagen Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Exagen Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Exagen Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Exagen Inc shares for Indian investors?

When investing in Exagen Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Exagen Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Exagen Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Exagen Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Exagen Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top